VS-5584 is a dual inhibitor targeting PI3K and mTOR pathways, which are key regulators of cell growth, survival, and metabolism. It has been primarily investigated for its potential in cancer therapy due to its ability to suppress signaling in tumor cells that rely on these pathways for proliferation. By inhibiting both PI3K and mTOR, VS-5584 can overcome limitations seen with single-pathway inhibitors, such as feedback activation that may reduce treatment efficacy. It has shown activity in preclinical models of hematologic malignancies and solid tumors, including leukemia and lymphoma, where dysregulation of the PI3K/mTOR axis is common. Its application is also being explored in combination with other anticancer agents to enhance therapeutic response and reduce drug resistance. Due to its mechanism, VS-5584 holds promise as a targeted therapy in cancers with specific genetic alterations in the PI3K pathway.